NCT06733441View on ClinicalTrials.gov

A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 16, 2024

Primary Completion Date

November 15, 2026

Study Completion Date

November 15, 2028

Conditions
Lymphoma
Interventions
DRUG

TLN-254

TLN-254 will be administered orally at a specified dose on specified days depending on treatment allocation.

DRUG

TLN-254

TLN-254 will be administered orally at a specified dose on specified days.

Trial Locations (5)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

63110

RECRUITING

Washington University School of Medicine, St Louis

94305

RECRUITING

Stanford Cancer Institute, Stanford

Unknown

RECRUITING

British Columbia Cancer Agency, Vancouver

All Listed Sponsors
lead

Treeline Biosciences, Inc.

INDUSTRY